Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

nventory fair value step-up whose total impact for the nine months ended September 30, 2012 is $49.4 million primarily relating to the acquisitions of iNova on December 21, 2011, Ortho Dermatologics on December 12, 2011, Dermik on December 16, 2011, Afexa on October 17, 2011, and Pedinol Pharmacal, Inc. on April 11, 2012.  For the nine months ended September 30, 2011 the impact of inventory fair value step-up is $48.9 million primarily relating to the merger of Legacy Valeant into Legacy Biovail and the acquisition of PharmaSwiss SA on March 10, 2011.(c) PP&E step-up/down represents the step-up/down to fair market value from Legacy Valeant's original cost resulting from the merger of Legacy Valeant into Legacy Biovail and subsequent acquisitions.(d) Costs associated with integration related tech transfers, $18.9 million.(e) Cost of Alliances represents the divestiture of 5FU and IDP-111 resulting from the acquisition of Dermik, $50.9 million for the nine months ended September 30, 2012 and the divestiture of Cloderm resulting from the Legacy Valeant into Legacy Biovail merger, $18.8 million for the nine months ended September 30, 2011. (f)  For the nine months ended September 30, 2012 SG&A primarily includes $26.8 million of Stock-based compensation which reflects the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail, acceleration of certain equity instruments and the expense associated with certain award modifications.  For the nine months ended September 30, 2011 SG&A primarily includes $50.0 million of Stock-based compensation which reflects the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail.(g) SG&A includes loss on assets held for sale/impairment.(h) Net expenses from the changes in fair value of contingent consideration for the nine months ended September 30, 2012 and 2011 of $23.2 million and $9.0
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health ... community pharmacies as winners of its prestigious Independent Pharmacy ... Conference , one of the nation,s largest gatherings of ... winners – family-owned pharmacies from Ohio ... Texas – were selected for implementing exceptionally ...
(Date:7/25/2014)... 2014 According to a new ... China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern ... Trends and Forecast (Value and Volume), 2013 - 2019", ... billion in 2012 and is expected to grow at ... reach USD 32.24 billion in 2019. Browse ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... 20 Accuray, Inc., (Nasdaq: ARAY ), ... announced today that it ranked number 113 on ... fastest growing technology, media, telecommunications, life sciences and clean ... percentage of fiscal year revenue growth during the period ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) third quarter ... Wednesday, October 27, 2010 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2010 third quarter financial results and other ...
Cached Medicine Technology:Accuray Ranked Number 113 Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2Accuray Ranked Number 113 Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:7/25/2014)... According to a new market research report "Machine ... ultrasound emission, lubricating oil analysis, corrosion monitoring, motor ... Global Forecast to 2014 - 2020", published by ... to reach $2.50 at a CAGR of 7.16% ... data Tables and 57 Figures spread through 353 ...
(Date:7/25/2014)... As reported by the New Orleans Advocate ... (7/3), the state of Louisiana has recently seen a ... than cocaine. Officials believe the increase is due to a ... of marijuana. However, both doctors and police confirm that that ... to call it “poison,” doctors have acknowledged that the Louisiana ...
(Date:7/25/2014)... Society of America (GSA) the nation,s ... aging has chosen Heather M. Young, PhD, ... as the 2014 recipient of the Doris Schwartz ... presented by GSA,s Health Sciences Section, is given ... of outstanding and sustained contribution to gerontological nursing ...
(Date:7/25/2014)... As reported by People Magazine in the ... Shore and Getting Sober (7/15), one of the most ... spoken out to the public about his personal transformation. Now, ... Situation admits that moving on with his life was a ... other drugs in 2012 and even spent some time in ...
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
Breaking Medicine News(10 mins):Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... (HealthDay News) -- Obesity and insulin resistance constitute a greater ... to a new study that found drinking modest amounts of ... For their study, published online May 23 in ... to either abstain from alcohol or drink one (women) or ...
... Mathematical models analyzing how a cholera outbreak ... the most effective vaccination strategies for preventing future ... The mathematical models employed to analyze a ... that mass vaccinations deployed strategically could prevent future ...
... impairment is evident early on in preschool children with ... children. Age of onset of first seizure is a ... first to evaluate cognitive impairment in children age three ... , a journal published by Wiley-Blackwell on behalf of ...
... June 2, 2011 In a multicenter ... found that higher doses of stereotactic radiation therapy ... patients with low-to-intermediate-risk prostate cancer. Results of ... Clinical Oncology , showed that stereotactic body radiation ...
... WEDNESDAY, June 1 (HealthDay News) -- People who become very afraid ... attack also seem to have more inflammation, an indicator that they ... less fearful, a small British study suggests. The finding, published ... us of the connection between the mind and the body," said ...
... Clinical Cardiology reveals that in men with ... libido, erectile dysfunction, and sexual performance. Chronic heart failure ... fatigue and exercise intolerance. HF patients experience decreased libido ... of pacemaker that paces the right and left ventricle, ...
Cached Medicine News:Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2Health News:UF researchers suggest cholera vaccination strategies for Zimbabwe 2Health News:Cognitive impairment seen in preschool children with epilepsy 2Health News:Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer 2Health News:Fear of Dying During Heart Attack May Make Matters Worse 2Health News:Fear of Dying During Heart Attack May Make Matters Worse 3
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: